We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
According to people familiar with the matter, Takeda is mulling a sale of some emerging-market drugs as the company looks to find ways to cut debt after its $62-billion takeover of Shire earlier this month, Bloomberg reported Monday.